Introduction

The Australian asthma/COPD market grew from $278m in 2006 to $333m in 2009. Its growth will slow considerably with the market projected to reach revenues of $354m in 2019. As new drugs launched will be me-too products or combinations of existing classes, Datamonitor assumes that these will be priced similarly to current brands in order to receive reimbursement, leading to a stabilizing market.

Reasons to Purchase

*Identify opportunities and threats that will impact the Australian asthma/COPD market as a whole and key brands and pipeline products in particular.

*Quantify the future size and scope of the Australian asthma/COPD market and predict the performance of its key compounds.

*Understand critical success factors in growing and defending asthma/COPD brand franchises from new entrants and generics.


Report Highlights

[Studien Infos ausblenden]

n/a
[Inhaltsverzeichnis ausblenden]